Yum! Brands Inc
Hotels, Restaurants & Leisure
Yum! Brands Inc (YUM) Stock News
The latest YUM headlines and market coverage — 4 recent stories, updated throughout the day.
- Zacks Investment Research·
Bear of the Day: Yum! Brands (YUM)
Yum! Brands receives a Zacks Rank #5 (Strong Sell) rating due to multiple challenges: a Taco Bell food safety outbreak impacting traffic, sticky inflation straining consumer spending, declining value perception from fast-food price increases, and concentration risk following the Pizza Hut sale. With only single-digit growth expected and significant underperformance versus the S&P 500 over five years, analysts recommend avoiding the stock.
- Zacks Investment Research·
YUMC or CMG: Which Is the Better Value Stock Right Now?
A comparison of two restaurant sector stocks shows Yum China Holdings (YUMC) as the superior value option compared to Chipotle Mexican Grill (CMG). YUMC has a stronger Zacks Rank (#2 Buy vs #3 Hold), lower valuation multiples (P/E of 14.05 vs 28.92, P/B of 2.39 vs 19.06), and a higher Value grade (A vs D), making it more attractive to value investors.
- Zacks Investment Research·Neutral
YUMC or CMG: Which Is the Better Value Stock Right Now?
In a comparison of two retail restaurant stocks, Yum China Holdings (YUMC) emerges as the better value option for investors. YUMC has a Zacks Rank of #2 (Buy) with improving earnings outlook, a forward P/E of 15.16, and a Value grade of A. In contrast, Chipotle Mexican Grill (CMG) has a Zacks Rank of #3 (Hold), a forward P/E of 33.63, and a Value grade of F, making it significantly more expensive on traditional valuation metrics.
- GlobeNewswire Inc.·Neutral
GNI Group Completes Acquisition of AYUMI Pharmaceutical
GNI Group Ltd. has completed its acquisition of Ayumi Pharmaceutical Holdings Co., Ltd. from Blackstone and other shareholders for approximately JPY 44.8 billion. The acquisition marks GNI Group's entry into Japan's pharmaceutical market, establishing what the company calls its 'Second Founding Phase' as a global biopharma company. Ayumi Pharmaceutical, with JPY 38.5 billion in annual revenue and over 80% market share in acetaminophen products, will operate as a wholly owned subsidiary while maintaining its brand names and product portfolio.